How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

102,459 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: anti-hypertensive/anti-proteinuric agents

Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: anti-hypertensive/anti-proteinuric agents ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 24 Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: anti- hypertensive agents Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES Non-diabetic Kidney (...) intervention with appropriate medical therapies is essential to address this public health burden and may reduce the progression of CKD and CV risk by up to 50%. [25] The objective of this guideline is to review currently available evidence in this regard and provide appropriate clinical recommendations. Recommendations in other guidelines, and the evidence underpinning these recommendations, have also been reviewed. The effect of specific anti-hypertensive agents on CKD progression has been discussed

2013 KHA-CARI Guidelines

162. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents

was $647 million. [23] A recent analysis of the health economic impact of end-stage kidney disease (ESKD) in Australia estimated that, at the end of 2007, hospital dialysis cost around $189 million per year. [24] Taken together, CKD is a significant contributor of morbidity and mortality, and represents a major expense to the health care system. Early intervention with appropriate medical therapies is essential to address this public health burden and may reduce the progression of CKD and CV risk by up (...) Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents ____________________________________________________________________________________________________________ Early Chronic Kidney Disease December 2011 Page 1 of 9 Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES a. We suggest that use of uric acid

2013 KHA-CARI Guidelines

163. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: glycaemic control

] ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 2 of 9 Taken together, CKD is a significant contributor of morbidity and mortality, and represents a major expense to the health care system. Early intervention with appropriate medical therapies is essential to address this public health burden and may reduce the progression of CKD and CV risk by up to 50%. [27] The objective of this guideline is to review currently available evidence in this regard and provide appropriate clinical recommendations (...) Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: glycaemic control ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 9 Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: glycaemic control Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES a. We recommend that patients with early (stage 1-3

2013 KHA-CARI Guidelines

164. Assessing the Effectiveness and Value of Drugs for Rare Conditions: A Technical Brief for the ICER Orphan Drug Assessment & Pricing Summit

Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. Boston, MA: Institute for Clinical & Economic Review; March 2017 2017. 62. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ (Clinical research ed). 2005;331(7523):1016-1019. 63. Winstone J, Chadda S, Ralston S, Sajosi P. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments. Orphanet (...) to patients with few or no existing treatment options. 2 Following on these successes, the market for orphan drugs is in a period of significant acceleration. As shown in Figure 1 below, worldwide sales of orphan drugs first reached $100 billion in 2015, but are expected to more than double by 2022 and will represent more than one-fifth of all prescription drug sales by that time. Figure 1. Orphan drug sales and market share trends. CAGR: Compound Annual Growth Rate One factor driving orphan drug costs

2017 California Technology Assessment Forum

165. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition Full Text available with Trip Pro

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition Guidelines for the Provision and Assessment of Nutrition Sup... : Pediatric Critical Care Medicine 1 mo and < 18 yr) critically ill patient expected to require a length of stay greater than 2 or 3 days in a PICU admitting medical, surgical, and cardiac patients. In total, 2,032 citations were (...) Medicine, to describe best practices in nutrition therapy in critically ill children. The target of these guidelines is intended to be the pediatric (> 1 mo and < 18 yr) critically ill patient expected to require a length of stay greater than 2 or 3 days in a PICU admitting medical, surgical, and cardiac patients. In total, 2,032 citations were scanned for relevance. The PubMed/Medline search resulted in 960 citations for clinical trials and 925 citations for cohort studies. The EMBASE search

2017 Society of Critical Care Medicine

166. Scientific elaboration of concepts for the generation of data related to clinical practice and their evaluation for the purpose of benefit assessments of drugs §35a Social Code Book V - Rapid report

of the data collected within the framework of the respective generation of data. Methods Information retrieval and assessment According to the project outline, the development of the concept for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a SGB V was supported by 3 modules: ? Empirical information from the benefit assessments of drugs according to the Act on the Reform of the Market for Medicinal Products (AMNOG, §35a SGB V). ? Exploratory (...) assessments ? Use of exact dates for patients, disease and events ? Detailed information on the drug therapy (active substance, dose, dose change, including dates) ? Timeliness (including rapid availability and punctuality of the required results) General criteria that may be relevant for registry studies for benefit assessments, depending on the research question ? Use of standard classifications (e.g. ICD-10) and terminology (e.g. MedDRA) ? Use of valid standard survey tools (questionnaires, scales

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

167. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. Full Text available with Trip Pro

bioequivalence, and safety, over a 24-h period after administration of both drugs. PK parameters were similar for PL-ASA and IR-ASA, and met FDA-criteria for bioequivalence. Regarding PD, both drugs also showed Cmin TxB2 values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) and > 99% inhibition of serum TxB2 ( ≥ 95% inhibition represents the cut-off for aspirin responders) along with similar results in several secondary PK/PD parameters. There were no serious adverse events (...) Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer. A liquid formulation of a novel pharmaceutical lipid-aspirin complex (PL-ASA) was designed to prevent this disruption. We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL

2019 Journal of thrombosis and thrombolysis Controlled trial quality: uncertain

168. U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016. (Abstract)

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016. National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visits for acute harms from nonmedical use of pharmaceuticals and to guide prevention efforts.Data collected in 2016 from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event (...) of estimated visits also involved non-pharmaceutical substances (52.9%, 95% CI=49.7%, 56.1%), including illicit drugs in 34.1% (95% CI=30.9%, 37.2%) and alcohol in 21.8% (95% CI=19.8%, 23.9%). Overall, benzodiazepines were implicated in 46.9% (95% CI=42.5%, 51.2%) of estimated emergency department visits for nonmedical use of pharmaceuticals but were the only substance implicated in just 6.5% (95% CI=5.1%, 7.9%). Prescription opioids were implicated in 36.2% (95% CI=30.8%, 41.7%) of estimated emergency

2019 American journal of preventive medicine

169. Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples. Full Text available with Trip Pro

of the promotional tools tested were mostly or sometimes motivating physicians to prescribe promoted drugs. The major tools that physicians agreed to be mostly motivated by are visits of medical representatives and drug samples while sales calls made by pharmaceutical companies are the less influential tool. Regarding gift acceptance, this study demonstrated that physicians consider gifts' acceptance as a non-ethical practice. Results showed that most physicians use free samples to treat their patients. We (...) Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples. Drug companies rely on their marketing activities to influence physicians. Previous studies showed that pharmaceutical companies succeeded to manage physicians prescribing behavior in developed countries. However, very little studies investigated the impact of pharmaceutical marketing strategies on prescribing pattern in developing countries, middle-eastern countries

2019 BMC health services research

170. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. (Abstract)

for NMIBC in the last 30 years, and product development for this disease has been stymied by difficulties in trial design and patient accrual.A workshop evaluating potential trial design for the development of therapies for NMIBC was held in San Diego, CA, in May 2013. Invited experts representing all stakeholders, including urology, medical oncology, radiation oncology, industry, and patient advocates, discussed development of products for all risk strata of NMIBC.The panel responded to specific (...) Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. To summarize the discussion at a public workshop, cosponsored by the U.S. Food and Drug Administration (FDA) and the American Urological Association, reviewing potential trial designs for the development of new therapies for non-muscle-invasive bladder cancer (NMIBC). There have been only 3 drug approvals

2014 Urology

171. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. Full Text available with Trip Pro

Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. Earlier antiretroviral therapy (ART) initiation reduces HIV-1 incidence. This benefit may be offset by increased transmitted drug resistance (TDR), which could limit future HIV treatment options. We analyze the epidemiological impact and cost-effectiveness of strategies to reduce TDR.We develop a deterministic mathematical model representing Kampala (...) can be averted by increasing second-line treatment (additional 7.1-10.2% reduction), followed by increased viral load monitoring (<2.7%) and pre-therapy genotyping (<1.0%). Only increasing second-line treatment is cost-effective, ranging from $1612 to $2234 (IQR $450-dominated) per QALY gained.While earlier treatment initiation will result in a predicted increase in the proportion of patients infected with drug-resistant HIV, the absolute numbers of patients infected with drug-resistant HIV

2014 Journal of the International AIDS Society

172. Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery.

Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery. Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery. (TOUTETDOU) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study

2014 Clinical Trials

173. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. (Abstract)

Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. Novel personalized therapeutic approaches are urgently needed for patients with metastatic clear cell renal cell carcinoma (ccRCC).We combined the development of a primary patient-derived ccRCC cell line with a phenotypic drug screen consisting of 101 approved anticancer compounds.We identified the MNNG HOS transforming (...) gene (MET)-anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitor crizotinib as the top hit of our drug screen, whereas compounds targeting the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathway showed no or only minor in vitro activity. Among the known major crizotinib targets MET, ALK, and ROS-1, only MET was expressed in our ccRCC cell line. Subsequent sequence analysis revealed a heterozygous R988C mutation of the MET gene and a VHL deletion in both

2014 Urologic oncology

174. HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey. (Abstract)

HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey. HIV pretreatment drug resistance (PDR) to NNRTIs in persons initiating ART is increasing in Mexico.To compare HIV PDR in eight sub-regions of Mexico.A large PDR survey was implemented in Mexico (September 2017-March 2018) across eight sub-regions. All larger clinics (which provide ART to 90% of all initiators) were included, allocating sample size using (...) the probability-proportional-to-size method. Both antiretroviral-naive and prior antiretroviral-exposed persons were included. HIV PDR levels were estimated from pol Sanger sequences obtained at a WHO-designated laboratory.A total of 2006 participants were enrolled from 74 clinics. PDR to NNRTIs was higher than to other drug classes (P < 0.0001), crossing the 10% threshold in the North-East, East, South-West and South-East. NNRTI PDR was higher in the South-West (P = 0.02), coinciding with the highest

2018 Journal of Antimicrobial Chemotherapy

175. Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression Full Text available with Trip Pro

Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression G protein-coupled receptor 56 (GPR56) is highly expressed in acute myeloid leukemia (AML) cells with high EVI1 expression (EVI1high AML). Because GPR56 is a transcriptional target of EVI1 and silencing of GPR56 expression induces apoptosis, we developed a novel drug to suppress GPR56 expression in EVI1high AML cells. For this purpose, we generated pyrrole

2018 Scientific reports

176. A blaOXA-181-harbouring multi-resistant ST147 Klebsiella pneumoniae isolate from Pakistan that represent an intermediate stage towards pan-drug resistance. Full Text available with Trip Pro

A blaOXA-181-harbouring multi-resistant ST147 Klebsiella pneumoniae isolate from Pakistan that represent an intermediate stage towards pan-drug resistance. Carbapenem resistant Klebsiella pneumoniae (CR-KP) infections are an ever-increasing global issue, especially in the Indian subcontinent. Here we report genetic insight into a blaOXA-181 harbouring Klebsiella pneumoniae, belonging to the pandemic lineage ST147, that represents an intermediate stage towards pan-drug resistance. The CR-KP (...) towards these last-resort drugs and illustrates the trajectory of resistance evolution of OXA-181-producing versions of the ST147 international risk clone.

2017 PLoS ONE

177. Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Full Text available with Trip Pro

Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Although cancer drug shortages are a persistent problem in oncology, little is known about the awareness and perspectives of the US population with respect to shortages.In 2016, we administered a 13-item cross-sectional survey to 420 respondents who were randomly selected from an online, probability-based sample demographically representative of the adult US population with respect to sex, age (...) , race/ethnicity, education, geography, and income. Analyses applied poststratification sampling weights to draw national inferences.Overall, 16% of respondents reported being aware of drug shortages. Those with a personal history of cancer were more likely to be aware (31% vs 14% [P = .03]). In the overall cohort, most reported wanting to be informed about a substitution due to shortage: 87% and 82% for major or minor differences in efficacy, and 87% and 83% for major or minor differences in side

2018 Cancer

178. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. Full Text available with Trip Pro

Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. Pretreatment HIV drug resistance (PDR) has the potential to affect treatment outcome and mortality. We present here the first nationally representative PDR study conducted in Cameroon.From February to July 2015, HIV-infected ART initiators were recruited from 24 randomly selected clinics situated in both urban and rural regions. Dried blood spot specimens were collected from study (...) participants at these clinics and centralized in a reference laboratory in Yaoundé, Cameroon, for drug resistance testing. HIV drug resistance mutations were identified using the Stanford algorithm.Overall, from the 379 participants recruited, 321 pol sequences were successfully interpreted. Two hundred and five sequences were from patients attending urban ART clinics and 116 from patients seen at rural facilities. Nine percent of sequences (29/321) were from participants reporting previous exposure

2018 Journal of Antimicrobial Chemotherapy

179. Possible associations of personality traits representing harm avoidance and self-directedness with medication adherence in Japanese patients with type 2 diabetes Full Text available with Trip Pro

Possible associations of personality traits representing harm avoidance and self-directedness with medication adherence in Japanese patients with type 2 diabetes Insufficient medication adherence in diabetes patients, of which numbers continue to increase globally, remains a critical issue. Medication adherence is multifactorial and determined by interactions among factors including socioeconomic status, health care team and system, condition, therapy, and patient-specific factors. On the other (...) were analyzed. Multivariate regression analysis of MMAS-8 scores revealed that higher TCI-SD was related to better adherence and experiencing drug-related side effects was related to poor adherence. Aging was significantly associated with better medication adherence in univariate regression analysis but became insignificant in multivariate regression.In diabetes patients, the anxiety reflected in TCI-HA tends to lower and the self-control reflected in TCI-SD tends to promote medication adherence

2018 Journal of pharmaceutical health care and sciences

180. Criteria for self-reported quantitative sleep characteristics of individuals who sought medical help for disturbed sleep – a survey of a representative sample of the Swedish population Full Text available with Trip Pro

Criteria for self-reported quantitative sleep characteristics of individuals who sought medical help for disturbed sleep – a survey of a representative sample of the Swedish population The public often seeks rule-of-thumb criteria for good or poor sleep, with a particular emphasis on sleep duration, sleep latency, and the number of awakenings each night. However, very few criteria are available.The present study sought to identify such criteria.Whether or not a person has sought medical help (...) for sleep problems was selected as an indicator of poor sleep. The group that was studied constituted a representative sample of the general Swedish population (N=1,128), with a response rate of 72.8%.Logistic regression analysis, with an adjustment for age and gender, showed an increased OR for a weekday sleep duration of ≤6 hour, (OR >2, and for <5 hour: OR >6). For weekend sleep, the value was ≤6 hour (OR >2). For awakenings per night, the critical value was ≥2 (OR >2, and for ≥5 awakenings: OR >9

2018 Nature and science of sleep

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>